Biogen, Inc. has been on the hunt during the past few years for outside assets that can help diversify its largely neurology-focused portfolio, and CEO Chris Viehbacher has been adamant that the company should pursue opportunities in adjacent areas where it has experience, such as immunology and rare diseases. The acquisition of Human Immunology Biosciences, Inc. (HI-Bio) for $1.15bn up front announced on 22 May checks both therapeutic area boxes.
Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal
Lead Drug Felzartamab Is Pipeline-In-A-Product
Known for its efforts in neurology, Biogen has been looking to make somewhat safer bets in immunology as it seeks to diversify and may achieve that with HI-Bio’s Phase III-ready felzartamab.
More from Deals
• By
Vertex, Sanofi, Hansoh and BMS/Myokardia have also recently exited deals. Callio launched with ADC technology from Hummingbird, plus more deals and tech transfer.
• By
The late-stage cupboard is looking bare but the German firm has its eyes on products with peak sales potential of over €500m.
• By
Jazz will pay $935m to acquire Chimerx and its drug for a rare form of brain cancer that has an FDA approval date in August. Dordaviprone might pair well with Ziihera, analysts said.
• By
Swiss major gains global rights to preclinical asset as it joins race for MRGPRX2 antagonists in urticaria, where some same-class rivals are already in Phase II.
More from Business
• By
Indian CDMOs could consider collaborating with allies in Europe amid a focused effort via a new industry body to counter existing challenges like China’s manufacturing, regulatory and policy advantages and a shortage of funding and talent in the country even as talk of US tariffs throws a new spoke in the wheel
• By
Competing with two Phase III competitors in the FGF21 analog class, Boston Pharma is hoping to begin Phase III this year. Novo Nordisk poses a new challenge with zalfermin.
• By
The company is building on its existing logistics and manufacturing for the radiopharmaceutical drug ITM-11, which delivered positive Phase III data.